PLAU and familial pancreatic carcinoma: The combination of traditional chemotherapy agents with novel and selective uPA-targeting drugs could be a revolutionary approach to pancreatic cancer treatment by limiting the characteristic uPAS-driven ECM proteolysis for an anti-metastatic response that could potentially offer considerable survival benefits for patients.